MediFind
Condition

Fascioliasis

Symptoms, Doctors, Treatments, Research & More

Latest Research

 

Triclabendazole in the treatment of human fascioliasis: a review.

Treatment Used: Triclabendazole
Number of Patients: 0
MediFind Summary

Overview: The study researched the effects of Triclabendazole to treat human fascioliasis.

Conclusion: Triclabendazole is safe and effective for human fascioliasis.

Abstract

Fascioliasis occurs on all inhabited continents. It is caused by Fasciola hepatica and Fasciola gigantica, trematode parasites with complex life cycles, and primarily affects domestic livestock. Humans become infected after ingestion of contaminated food (typically wild aquatic vegetables) or water. Fascioliasis may be difficult to diagnose as many symptoms are non-specific (e.g. fever, abdominal pain and anorexia). Treatment options are limited, with older effective therapies such as emetine and bithionol no longer used due to safety issues and unavailability, and most common anthelminthics having poor efficacy. Clinical trials conducted over a 25-year period, together with numerous case reports, demonstrated that triclabendazole has high efficacy in the treatment of human fascioliasis in adults and children and in all stages and forms of infection. Triclabendazole was approved for human use in Egypt in 1997 and in France in 2002 and a donation program for the treatment of fascioliasis in endemic countries was subsequently established by the manufacturer and administered by the World Health Organization. Here the published data on triclabendazole in the treatment of human fascioliasis are reviewed, with a focus on more recent data, in light of the 2019 US Food and Drug Administration approval of the drug for use in human infections.

Authors
Preetam Gandhi, Esther Schmitt, Chien-wei Chen, Sanjay Samantray, Vinay Venishetty, David Hughes

View Article From Source